戻る Agenda
Session 6: Track B: Emerging Technologies and Therapies
Session Chair(s)
Fiona M Frappier, PHD
Senior Policy Analyst, Health Canada, Canada
Emerging technologies have started to disrupt whole industries and in doing so are demonstrating their role as amplifiers for solutions in health outcomes. This session will describe lessons learned in bringing novel therapies through to market. Strategic elements of technology transfer, securing intellectual property, and financing in the Canadian context will focus on overcoming the first valley of death. Key enablers and thought leaders will provide examples of emerging technology companies and spin offs they have shepherded through critical steps.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe key considerations in early-stage biotech investing
- Identify a range of Canadian small start ups
- List an overview of lessons learned from Canadian case studies
Speaker(s)
Siofradh McMahon, MSC
Senior Manager, Clinical Translation and Regulatory affairs, CCRM, Canada
Collaborating to Get Through the Valley(s) of Death in Regenerative Medicine
Maxwell Morgan, JD, LLM
Lead Legal & Policy Advisor, Structural Genomics Consortium (SGC), Canada
Open Science Opportunities for Development and Commercialization of Novel Therapies
Nadine Kolas
Senior Policy Analyst , Health Canada, Canada
Regulation of Advanced Cell Therapies for Regenerative Medicine